Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

https://www.soho2020.com/

 

Acalabrutinib vs. SoC for R/R CLL: Do the Final Results of ASCEND Trial Confirm Favorable Efficacy and Safety of the BTKi Option?

65 views
December 14, 2020
Comments 0
Login to view comments. Click here to Login